强化血糖控制对糖尿病伴急性心肌梗死患者经皮冠状动脉介入治疗术后心肌组织灌注及心室功能的影响

目的 观察强化血糖控制对糖尿病伴急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)术后心肌组织灌注及心室功能的影响.方法 68例2型糖尿病伴AMI患者完全随机分为糖尿病常规治疗组(34例)和糖尿病强化治疗组(34例),并以69例糖耐量正常NGT的AMI患者为NGT对照组.常规治疗为诺和灵30R皮下注射,维持血糖在8.0～11.1 mmol/L;强化治疗为静脉滴注胰岛素和(或)胰岛素泵治疗,维持血糖在4.4～6.1 rmnol/L.所有患者均于发病后24 h内行PCI,治疗后行心肌呈色分级(MBG),评价心肌微循环灌注情况,并于术后1周及1个月行心脏超声心动图检查,分别测定左心室射血分数、心指数,评价心室功能.结果 3组患者PCI术后心肌梗死溶栓试验(TIMI)3级的比率差异无统计学意义(P>0.05),糖尿病常规治疗组和糖尿病强化治疗组患者MBG 2-3级比例均明显低于NGT对照组(64.7%,82.3%比94.2%.均P<0.01),PCI术后1周和1个月时糖尿病强化治疗组心指数明显高于糖尿病常规治疗组[(3.17+0.42)L/(min·m2)比(2.62±0.43)L/(min·m2),(3.85±0.51)L/(min·m2)比(3.14±0.57)L/(min·m2),P<0.05],而糖尿病强化治疗组心指数和NGT对照组间差异无统计学意义(P>0.05);3组患者术后1周与术后1个月比较心指数均改善且差异有统计学意义(均P<0.05);NGT对照组左心室射血分数高于糖尿病常规治疗组和糖尿病强化治疗组(P<0.01),PCI术后1个月NGT对照组和糖尿病强化治疗组左心室射血分数较术后1周时明显改善(P<0.05),糖尿病常规治疗组亦有一定改善,但差异无统计学意义.结论 强化血糖控制可明显改善糖尿病伴AMI患者急诊PCI术后的心肌组织灌注及心室功能.

Abstract：

Objective To examine the effects of intensive glucose control on myocardial tissue perfusion and ventricular function in post-percutaneous coronary intervention(PCI)diabetes mellitus(DM)patients with acute myocardial infarction(AMI).Methods Sixty-eight DM patients with AMl were divided into two groups:DM routine treatment group(n=34)and DM intensive treatment group(n=34),and 69 AMI patients with normal glucose tolerance(NGT)as NGT control group.DM routine treatment group were treated with novolin 30R.to maintain blood glucose in 8.0～11.1mmol/L;DM intensive treatment group were treated with insulin.and(or)insulin pump,to maintain blood glucose in 4.4-6.1 mmol/L.All patients underwent emergency coronary angiography after PCI.We estimated the myocardial tissue perfusion according to the myocardial blush grade(MBG).The left ventricular ejection fraetio(LVEF)and cardiac index(CI)were measured in all patients at 1 week and l month after PCI to estimate ventricular function.Resuits There was no significant difference in TIMI Grade 3 after PCI among three groups(P>0.05),and the percentage of efficient reperfusion in DM group was significantly lower than NCT control groups(64.7%,82.3%vs 94.2%,P<0.01).The CI value was much higher in NGT intensive treatment group than DM routine treatment group(P<0.01),and there was no significant difference between DM intensive treatment group and NGT control group at 1 week and 1 month after PCI(P>0.05),but the CI value was significandy improved in all three groups at 1 month than at 1 week after PCI(P<0.05).The LVEF was much higher in NGT control group than DM groups(P<0.01),and significandy improved in NGT control group and DM intensive treatment group at 1 month than at 1 week after PCI(P<0.05),but there was no significant improved in DM routine treatment group(P>0.05).Condusion Intensive glucose control may significantly improve myocardial tissue perfusion and ventricular function after PCI in DM patients with AMI.     

阿托伐他汀对经皮冠状动脉介入术患者心肌损伤的保护作用

目的 探讨阿托伐他汀对经皮冠状动脉介入术（ PCI）患者心肌损伤的保护作用.方法 285例行PCI患者随机分为观察组（n=140）和对照组（n=145）,两组均按PCI常规治疗,观察组PCI术前7d开始口服阿托伐他汀（40 mg/d）,对照组术前未服用他汀类降脂药.观察两组肌酸激酶同功酶-MB（CK-MB）、肌钙蛋白Ⅰ（TnI）水平变化情况.结果 观察组TnI及CK-MB峰值分别为（0.12±0.26） μg/L、（2.61±3.07）μg/L明显低于对照组的（0.51±1.14） μg/L、（6.85±14.38） μg/L（t=3.951、3.414,均P＜0.05）.结论 PCI术前1周采用阿托伐他汀治疗可减少PCI术后的心肌损伤.     

瑞舒伐他汀短期干预对急性冠状动脉综合征患者高敏C反应蛋白及血管性血友病因子和内皮依赖性血管功能的影响

目的 研究瑞舒伐他汀短期干预对急性冠状动脉综合征(ACS)患者血清高敏C反应蛋白(hsCRP)和血管性血友病因子(vWF)水平以及内皮依赖性血管舒张功能的影响.方法 将62例ACS患者完全随机分为他汀组和常规组,各31例,常规组施以常规和安慰剂治疗,他汀组在常规治疗基础上加服瑞舒伐他汀20 mg/d,疗程8周,并于治疗前后分别测定血清hs-CRP、vWF和内皮依赖性血管舒张功能的变化.结果 治疗8周后,常规组的hs-CRP、TC、TG、HDL-C、LDL-C、vWF水平分别为(12.41±5.36)mg/L、(6.31±0.80)mmol/L、(2.65±0.57)mmol/L、(1.33±0.28)mmol/L、(4.20±0.98)mmol/L、(150.68±27.85)%.他汀组上述指标分别为(6.15±2.07)mg/L、(5.87±0.63)mmol/L、(2.38±0.48)mmol/L、(1.48±0.27)mmol/L、(2.91±0.92)mmol/L、(127.46±18.25)%.他汀组治疗后hs-CRP、TG、HDL-C、LDL-C、vWF与治疗前比较,差异有统计学意义(P＜0.01).他汀组治疗后TC、HDL-C与常规组治疗后比较,差异有统计学意义(P＜0.05);他汀组治疗后hs-CRP、LDL-C、vWF与常规组治疗后比较,差异有统计学意义(P＜0.01).结论 应用瑞舒伐他汀对ACS进行干预,在有效调脂的同时可显著降低hs-CRP和vWF水平,改善血管内皮功能,有利于动脉粥样硬化斑块的稳定.

Abstract：

Objective To study the effects of short-term rosuvastatin therapy on high sensitive C-reactive protein (hs-CRP), von Willebrand factor(vWF) and endothelium dependent vasodilatation function in patients with acute coronary syndrome(ACS). Methods Totally 62 patients with ACS were randomly divided into the statin group (n =31 ) and control group (n =31 ). The patients in statin group were treated with Rosuvastain 20 mg/day besides conventional therapy; the patients in control group were treated only with conventional therapy and placebo.The course of therapy was 8 weeks. Plasma levels of hs-CRP and vWF, endothelium dependent vasodilatation function were measured before and after treatment. Results The plasma levels of hs-CRP and vWF in statin group were decreased significantly (P ＜0.01 ), also endothelium dependent vasodilatation function were improved than the patients in control group after 8 weeks. Conclusion It is suggested that short-term therapy with rosuvastatin in patients with ACS could reduces the levels of hs-CRP and vWF and improve the function of endothelium dependent vasodilatation, thus it promotes the stabilization of atheroselerotic plaque.     

经皮冠状动脉介入治疗对缺血性心肌病患者左心室功能的影响

目的 探讨经皮冠状动脉介入(PCI)治疗对缺血性心肌病(ICM)患者左心室功能的影响.方法 将65例ICM患者随机分为PCI治疗组(32例)和药物治疗组(33例).PCI治疗组接受PCI和药物治疗;药物治疗组接受单纯药物治疗.随访1年,6和12个月时行心脏超声心动图检查,比较2组患者左心室舒张末容积(LVEDV)和左心室射血分数(LVEF)以及1年心血管事件发生情况.结果 PCI治疗组左心室功能改善优于药物治疗组[LVEF:治疗后6个月(38.0±2.4)%比(36.0±2.8)%,治疗后12个月(43.0±2.1)%比(40.0±2.5)%,P＜0.05],PCI治疗组1年内急性心肌梗死、急性左心衰竭、心源性死亡以及因心功能不全和/或严重心肌缺血再次住院发生率低于药物治疗组[分别为6.2%比24.2%,9.4%比30.3%,3.1%比18.2%,18.7%比54.5%,均P＜0.05].结论 PCI对ICM治疗有效,与单纯药物治疗比较,PCI加药物治疗能更有效地改善患者左心室功能及减少心血管事件发生.

Abstract：

Objective To investigate the effect of percutaneous coronary intervention (PCI) on left ventricular function of patients with ischemic cardiomyopathy. Methods The 65 patients with ischemic cardiomyopathy were divided into PCI group(32 cases) and medicine group(33 cases). PCI group accepted PCI and medicine, medicine group accepted medicine only. They were followed up for one year. Transthoracic eahocardiography (TTE) in sixth and twelfth months were examined. The LVEDV, LVEF and cardiovascular events in one year between two groups were compared. Results The improvement of left ventricular function in PCI group was better than that in medicine group. [LVEF:sixth month after treatment(38.0±2.4)% vs (36.0±2.8)%,twelfth month(43.0± 2.1)% vs (40.0±2.5)%,P＜0.05]The incidence rates of the events of acute myocardial infarction,acute left heart failure, cardiac death, rehospitalization due to cardiac insufficiency or severe myocardiac ischemic in PCI group were lower than those in medicine group in one year[6.2% vs 24.2% ,9.4% vs 30. 3% ,3.1% vs 18.2% ,18.7% vs 54.5% ,P＜0.05]. Conclusions It is effective to treat the ischemic cardiomyopathy with PCI. The PCI combined with medicine is superior to medicine only in improving left ventricular function and decreasing cardiovascular events in ischemic cardiomyopathy.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

强化他汀类药物治疗对非ST段抬高急性冠状动脉综合征患者经皮冠状动脉介入治疗围术期炎症反应和内皮损伤的影响

目的观察经皮冠状动脉介入（PCI）术前短期强化他汀类药物治疗对非ST段抬高急性冠状动脉综合征（NSTE—ACS）患者高敏C反应蛋白（hs—CRP）和血管性皿友病因子（vWF）的影响。方法入选符合标准的NSTE—ACS行PCI患者100例,完全随机分为研究组和对照组,各50例。对照组和研究组均接受标准药物治疗,并分别于PCI术前开始7d开始服用辛伐他汀20mg／次、1次／d和阿托伐他汀40mg／次、1次／d,连用7d。术后2组均服用阿托伐他汀20mg／次,1次／d。术日,患者均按标准程序行冠状动脉造影和PCI。检测并记录入院次日、手术当日、术后24h血hs—CRP和vwF水平。结果①PCI术当日,2组hs—CRP均较本组治疗前下降;与对照组比较,研究组hs—CRP下降幅度更明显,组间差异有统计学意义[（2．1±1．6）mg／L比（3．4±2．3）mg／L,P〈0．05]。PCI术后24h,2组hs—CRP均较本组PCI术当日上升;研究组与对照组间的差异有统计学意义[（2．5±1．9）mg／L比（3．7±3．4）mg／L,P〈0．05]。②PCI术后24h,对照组vWF值较本组他汀类药物治疗前和PCI术当日均明显升高,与治疗后的差异有统计意义（P〈0．05）;研究组vWF值较对照组明显降低,组间差异有统计学意义[（151±54）μg／L比（204±125）Ixg／L,P〈0．05]。结论PCI术前短期强化他汀类药物治疗能够减低NSTE—ACS患者围术期hs—CRP水平,并减少内皮损伤。     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

目的探讨不同剂量阿托伐他汀治疗对ACS（急性冠状动脉综合征）患者急诊经皮冠状动脉介入治疗（PCI）术后粘附分子水平的影响。方法入选88例ACS患者随机分为：A常规治疗组30人,B阿托伐他汀标准剂量组29人,C阿托伐他汀负荷剂量组29人。三组分别于术前、术后3、7、14天抽血,用ELISA法测定血清可溶性细胞间粘附分子（soluble intercellular adhesionmolecule-1,sICAM-1）、血管细胞粘附分子（soluble vascular cell adhesion molecule-1,sVCAM-1）水平。结果阿托伐他汀80mg,d组在治疗第7天,两种血清粘附分子水平显著低于阿托伐他汀10mg／d组,两组sICAM-1分别是（68．35±23．80）μg／L和（131．45±29．12）μg／L、sVCAM-1分别是（251．65±36．61）μg／L和（334．87±32．98）μg／L。此外,两组阿托伐他汀治疗剂量均显示可以显著减少两种粘附分子的水平（P〈0．05）,观察时段内各组对血脂水平影响无显著性差异（P〉0．05）结论阿托伐他汀治疗组比常规治疗组可以显著降低粘附分子水平,其中阿托伐他汀术后负荷剂量冲击治疗,较标准剂量更能显著降低血清粘附分子水平,从而抑制PCI术后的炎症反应的发生,减少术后再狭窄的发生。     

高龄非ST段抬高型急性冠状动脉综合征患者经皮冠状动脉介入术前强化他汀类药物治疗对围术期血小板相关参数的影响

目的：探讨经皮冠状动脉介入（ PCI）术前短期、强化他汀类药物治疗对高龄非ST段抬高型急性冠状动脉综合征患者血小板相关参数的影响。方法选取首都医科大学附属北京安贞医院因不稳定型心绞痛或非ST段抬高型心肌梗死行PCI的患者138例。 PCI术前12 h用随机数字表法分为2组：他汀常规治疗（阿托伐他汀20 mg/d）组70例,强化治疗（阿托伐他汀80 mg负荷剂量,随之40 mg/d）组68例。入院后检测基线血小板参数[血小板计数、平均血小板体积（ MPV）、血小板分布宽度（ PDW）、大血小板比例（P-LCR）]。 PCI术后第1、5天复查血小板参数,检测花生四烯酸（AA）和二磷酸腺苷（ADP）诱导的血小板聚集率。结果2组患者入院后基线、PCI术后第1、5天的血小板计数、MPV、PDW、P-LCR比较,差异均无统计学意义（均P＞0．05）。与基线比较,常规治疗组PCI术后第1天血小板计数下降,MPV、PDW和P-LCR增加,差异均有统计学意义[（206±62）×10^9/L比（210±60）×10^9/L、（10．8±0．9）fL比（10．6±0．9）fL、（12．8±1．9）％比（12．5±1．9）％、（32±8）％比（30±8）％]（P＜0．05）;常规治疗组PCI术后第5天血小板计数、MPV、PDW、P-LCR与基线比较,差异无统计学意义（P＞0．05）。强化治疗组PCI术后第1天血小板计数、MPV、PDW及P-LCR与基线比较,差异无统计学意义（ P＞0．05）;PCI术后第5天MPV及P-LCR与基线比较,差异有统计学意义[（10．6±1．0）fL比（10．8±1．0）fL、（30±9）％比（31±8）％]（P＜0．05）。2组PCI术后第1、5天AA和ADP诱导的血小板聚集率比较,差异无统计学意义（P＞0．05）;组内AA和ADP诱导的血小板聚集率比较,差异无统计学意义（ P＞0．05）。结论对于高龄非ST段抬高型急性冠状动脉综合征患者,强化他汀类药物治疗能有效抑制PCI术后MPV、L-PCR等的升高,抑制介?     

速效心痛滴丸对急性心肌梗死患者心血管事件发生的影响

目的：评价急性心肌梗死（ AMI）患者经皮冠脉支架置入术（ PCI）后联合速效心痛滴丸,观察其对心血管事件的影响。方法纳入2011年1月至2013年6月确诊AMI并接受PCI治疗的患者96例,随机分为对照组（ n＝48）和治疗组（ n＝48）,对照组行常规术后治疗,治疗组在对照组治疗方案的基础上加用速效心痛滴丸（7粒,tid）,观察两组180 d后心血管事件（包括心绞痛、心功能不全、再发心肌梗死和心源性猝死）的发生情况是否存在统计学差异。结果随访期间,治疗组较对照组心功能不全与心绞痛发生率降低,差异有统计学意义（P＜0．05）,随访结束心功能获得明显改善;两组均无再发心肌梗死或心源性猝死。结论 AMI患者PCI术后常规治疗方案的基础上联合应用速效心痛滴丸,可降低心血管事件发生风险。     

强化他汀治疗对合并睡眠呼吸暂停综合征的冠心病患者PCI术后的影响

目的研究不同剂量阿托伐他汀对合并睡眠呼吸暂停综合征的冠心病患者PCI术后的影响。方法将PCI术后的冠心病患者依据多导睡眠呼吸监测结果随机分为不合并睡眠呼吸暂停综合征组(对照组,90例)及合并睡眠呼吸暂停综合征组(SAS组,90例),之后再依据阿托伐他汀应用剂量,分别随机分为10 mg、20 mg、40 mg剂量组各30例;分别检测两组患者C反应蛋白(CRP)及白细胞介素-6(IL-6)水平;随访6个月内各剂量组心血管事件发生例数;PCI术后6个月复查冠脉造影,利用Gensini评分系统,分别对各剂量组患者进行冠状动脉病变程度评分。结果入院时,SAS组患者的CRP及IL-6水平高于对照组;PCI术后6个月,SAS 10 mg、20 mg剂量组CRP、IL-6水平高于对照组(P<0.05)。随访6个月后,SAS 10 mg、20 mg剂量组心绞痛、心力衰竭、心律失常发生例数多于对照组(P<0.05),但40 mg剂量组间比较差异无统计学意义(P>0.05);此外,SAS组患者的心血管事件发生率随着阿托伐他汀剂量的增大逐渐降低,且不同剂量组间差异有统计学意义(P<0.05);PCI术后6个月时,SAS组10 mg、20 mg组患者的Gensini积分较对照组明显偏高(P<0.05),但40 mg剂量组间比较差异无统计学意义(P>0.05)。结论强化他汀治疗可以降低合并睡眠呼吸暂停综合征冠心病患者PCI术后的炎症因子水平及心血管事件发生率,同时可以有效降低冠状动脉的病变程度。     

经皮冠状动脉介入术治疗冠状动脉左主干病变疗效观察

目的 观察经皮冠状动脉介入术(PCI)治疗无保护冠状动脉左主干(ULMCA)病变的疗效.方法 对40例ULMCA病变患者采用PCI治疗,随访6～20个月,观察心血管不良事件(MACE)的发生情况.结果 所有患者经PCI治疗即时成功率100.0％,术中无严重并发症.住院期间未发生严重心血管不良事件.术后随访6～20(7±2)个月,术后4周发生急性心肌梗死l例,CAG证实回旋支开口亚急性支架内血栓形成,再次PCI治愈;术后动员28例患者在6～12个月进行CAG复查,其中回旋支开口支架内再狭窄3例,左主干远端-前降支开口再狭窄1例,2例再狭窄患者有心绞痛症状,3例再次行PCI,无需要CABG患者.随访期间无死亡病例.心血管不良事件总的发生率12.5％ (5/40),再狭窄率10.0％(4/40).结论 对经过选择的ULMCA病变进行PCI是安全可行的,有良好的近远期预后.     

急性冠状动脉综合征经皮冠状动脉介入治疗中血糖波动和不良事件的关系

目的 分析急性冠状动脉综合征患者经皮冠状动脉介入治疗(PCI)术后住院期间的血糖波动与患者预后的相关性.方法 总结2009年1-12月在北京安贞医院心内科以急性冠状动脉综合征合并糖尿病入院并进行PCI治疗的患者1723例,且住院时间不少于3d,住院期间每日监测血糖不少于4次的病例资料,根据有无心血管不良事件及死亡分为不良事件组(84例)、无不良事件组(1639例),计算2组患者PCI术后3d每天的血糖值,根据每天最高血糖与最低血糖计算术后3d的血糖最大波动幅度,计算术后3d血糖标准差及血糖最大波动幅度的均值,观察血糖波动与不良心血管事件发生及死亡的相关性.结果 不良事件组及无不良事件组术后3d平均血糖(MBG)分别为(10.6±2.2)、(11.3±1.5)mmol/L,平均血糖标准差分别为(3.6±1.4)、(1.7±0.7) mmol/L,最大血糖波动幅度分别为(11.3±3.5)、(7.6±2.4) mmol/L;2组急性冠状动脉综合征伴糖尿病患者PCI术后,MBG水平无明显差别,组间差异无统计学意义(P＞0.05);不良事件组血糖标准差明显高于无不良事件组,组间差异有统计学意义(P＜0.05).不良事件组日最大血糖波动幅度明显大于无不良事件组,组间差异有统计学意义(P＜0.01).结论 提示急性冠状动脉综合征伴糖尿病患者PCI术后血糖波动可能增加不良心血管事件和病死率.     

不同剂量阿司匹林在冠心病行经皮冠状动脉介入术后的应用效果

目的探讨不同剂量阿司匹林在冠心病行经皮冠状动脉介入术（PCI）后的应用效果。方法选取本院2011年2月-2013年2月行PCI的202例冠心病患者为研究对象,简单抽样法随机分为A、B两组,每组101例,A组给予低剂量阿司匹林（0.1 g/d）,B组给予高剂量阿司匹林（0.3 g/d）。比较两组治疗后6个月随访期内不良脑血管事件发生情况,记录其各项指标的变化情况。结果两组治疗前各项指标比较,差异无统计学意义（P〉0.05）;治疗后6、12个月各指标均较治疗前明显降低（P〈0.05）;A、B两组治疗后6、12个月血栓烷B2及总胆固醇组间比较,差异无统计学意义（P〉0.05）;治疗后6个月,B组三酰甘油（TG）及低密度脂蛋白胆固醇（LDL-C）水平明显低于A组,差异有统计学意义（P〈0.05）;治疗后12个月两组各项指标均较治疗6个月后降低,但差异无统计学意义（P〉0.05）。治疗后A组不良脑血管事件发生率为13.86%,B组为15.84%,两组差异无统计学意义（χ2=0.69,P〉0.05）。结论对冠心病患者行PCI后给予低剂量阿司匹林,可有效降低不良脑血管事件发生率,安全性较高,具有临床推广价值。     

Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?

Abstract

Intensive statin treatment has proved beneficial in patients with acute coronary syndromes. However, this benefit may apply only to those undergoing percutaneous coronary intervention (PCI). Loading, preloading or reloading with high dose(s) of a statin may decrease major adverse cardiac events, revascularization of both target and non-target vessels as well as myocardial necrosis after PCI. It seems that different actions of statins are responsible for their protective role in target vessel and non-target vessel revascularization procedures. This editorial discusses the results of statin loading trials and comments on the possible mechanisms involved.     

葛兰心宁软胶囊对非ST段抬高型急性冠状动脉综合征患者介入术后内皮功能的影响

目的观察葛兰心宁软胶囊对非sT段抬高型急性冠状动脉综合征（NSTE—ACS）患者经皮冠状动脉介入（PCI）术后内皮功能的影响。方法将入院行PCI术的100例NSTE—ACS患者完全随机分为对照组和观察组,各50例。对照组给予常规治疗,观察组在常规治疗基础上加服葛兰心宁软胶囊4粒（0．58g／粒）,3次／d,2组疗程均1个月。于PCI术前空腹12h和术后1个月抽血检测患者血脂、NO和内皮素1水平;PCI术前和术后1个月采用高分辨率彩色多普勒超声仪测定患者肱动脉内皮依赖性血流介导的血管舒张功能（FMD）。结果与PCI术前相比,观察组患者术后1个月血脂水明显改善,差异有统计学意义（P〈0．05）;与对照组相比,用药1个月后观察组TG、TC、LDL—C明显降低,差异有统计学意义（P〈0．05）;2组患者PCI术后1个月内皮素1较术前降低[对照组：（66±10）ng／L比（74±18）ng／L,观察组：（61±15）ng／L比（75±24）ng／L,P〈0．05],NO较术前增加[对照组：（101±8）μmol／L比（79±8）μmol／L,观察组：（131±7）μmol／L比（79±11）μmol／L,P〈0．05],其中观察组较对照组升高更为明显（P〈0．05）;对照组与观察组患者PCI术后1个月的FMD较术前升高[（8．6±1．4）％比（5．8±2．2）％,（9．0±1．3）％比（5．8±2．1）％,P〈0．05],观察组FMD升高更明显（P〈0．05）。结论NSTE—ACS患者PCI术后在常规治疗基础上加用葛兰心宁软胶囊能进一步改善内皮功能和血脂水平。